Translate Bio (Translate Bio) Accounts Receivable : $0.0 Mil (As of Jun. 2021)

View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Translate Bio's accounts receivables for the quarter that ended in Jun. 2021 was $0.0 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Translate Bio's Days Sales Outstanding for the quarter that ended in Jun. 2021 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Translate Bio's Net-Net Working Capital per share for the quarter that ended in Jun. 2021 was $2.32.

Translate Bio Accounts Receivable Historical Data

The historical data trend for Translate Bio's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Accounts Receivable Chart

Translate Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Accounts Receivable

Translate Bio Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Accounts Receivable	Get a 7-Day Free Trial														-	-	-	-	-

Translate Bio Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Translate Bio Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Translate Bio's Days Sales Outstanding for the quarter that ended in Jun. 2021 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	72.649	*	91
=	0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Translate Bio's accounts receivable are only considered to be worth 75% of book value:

Translate Bio's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2021 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(667.198	+	0.75 * 0	+	0.5 * 0	-	492.233
-	0	-	0)	/	75.3437
=	2.32

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Translate Bio Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Translate Bio's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Translate Bio (Translate Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Hartwell Avenue, Lexington, MA, USA, 02421

Website

http://www.translate.bio

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Executives

Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr	director, officer: Chief Executive Officer, other: President	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess	officer: Chief Operating Officer, CLO, other: Secretary	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc.	10 percent owner	300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c.	10 percent owner	10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma	10 percent owner	10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri	director	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman	director	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge	director	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch	director
Robert J. Meyer	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier	officer: Chief Medical Officer	255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109